Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-albuminuric effects of dapagliflozin in type 2 diabetes
2014-000157-37Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in 24-hour albuminuria. Started Mar 2014; status: active.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2014-000157-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000157-37.